Circulating Tumor Cell Detection in Lung Cancer: But to What End?

The understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving under...

Full description

Bibliographic Details
Main Authors: Véronique Hofman, Simon Heeke, Charles-Hugo Marquette, Marius Ilié, Paul Hofman
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/11/2/262
id doaj-d030b8e165eb44ed92922988865cc76f
record_format Article
spelling doaj-d030b8e165eb44ed92922988865cc76f2020-11-24T23:31:17ZengMDPI AGCancers2072-66942019-02-0111226210.3390/cancers11020262cancers11020262Circulating Tumor Cell Detection in Lung Cancer: But to What End?Véronique Hofman0Simon Heeke1Charles-Hugo Marquette2Marius Ilié3Paul Hofman4Laboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, FranceLaboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, FranceTeam 4, IRCAN, FHU OncoAge, University Côte d’Azur, CNRS, INSERM, 06107 Nice CEDEX 02, FranceLaboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, FranceLaboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, FranceThe understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving understanding within the domain of thoracic oncology. However, the use of these CTCs as prognostic and predictive biomarkers has not been adopted to the same extent as circulating free DNA (cf-DNA) in plasma, in the daily practice of thoracic oncologists. However, recent technological advances have firmly put the detection and characterization of CTCs in thoracic oncology back on the agenda, and have opened up perspectives for their routine clinical use. This review discusses the major advances of using CTCs in the domain of thoracic oncology, as well as the envisaged short- and long-term prospects.https://www.mdpi.com/2072-6694/11/2/262circulating tumor cellsliquid biopsylung cancerpersonal medicinetechniquesxenograft
collection DOAJ
language English
format Article
sources DOAJ
author Véronique Hofman
Simon Heeke
Charles-Hugo Marquette
Marius Ilié
Paul Hofman
spellingShingle Véronique Hofman
Simon Heeke
Charles-Hugo Marquette
Marius Ilié
Paul Hofman
Circulating Tumor Cell Detection in Lung Cancer: But to What End?
Cancers
circulating tumor cells
liquid biopsy
lung cancer
personal medicine
techniques
xenograft
author_facet Véronique Hofman
Simon Heeke
Charles-Hugo Marquette
Marius Ilié
Paul Hofman
author_sort Véronique Hofman
title Circulating Tumor Cell Detection in Lung Cancer: But to What End?
title_short Circulating Tumor Cell Detection in Lung Cancer: But to What End?
title_full Circulating Tumor Cell Detection in Lung Cancer: But to What End?
title_fullStr Circulating Tumor Cell Detection in Lung Cancer: But to What End?
title_full_unstemmed Circulating Tumor Cell Detection in Lung Cancer: But to What End?
title_sort circulating tumor cell detection in lung cancer: but to what end?
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2019-02-01
description The understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving understanding within the domain of thoracic oncology. However, the use of these CTCs as prognostic and predictive biomarkers has not been adopted to the same extent as circulating free DNA (cf-DNA) in plasma, in the daily practice of thoracic oncologists. However, recent technological advances have firmly put the detection and characterization of CTCs in thoracic oncology back on the agenda, and have opened up perspectives for their routine clinical use. This review discusses the major advances of using CTCs in the domain of thoracic oncology, as well as the envisaged short- and long-term prospects.
topic circulating tumor cells
liquid biopsy
lung cancer
personal medicine
techniques
xenograft
url https://www.mdpi.com/2072-6694/11/2/262
work_keys_str_mv AT veroniquehofman circulatingtumorcelldetectioninlungcancerbuttowhatend
AT simonheeke circulatingtumorcelldetectioninlungcancerbuttowhatend
AT charleshugomarquette circulatingtumorcelldetectioninlungcancerbuttowhatend
AT mariusilie circulatingtumorcelldetectioninlungcancerbuttowhatend
AT paulhofman circulatingtumorcelldetectioninlungcancerbuttowhatend
_version_ 1725538603655757824